Dr. Christian Lehmann
Dr. Christian Lehmann is Professor of Anesthesia, Pharmacology, Microbiology & Immunology and Physiology & Biophysics at Dalhousie University, Halifax, NS. He is also cross-appointee in the Faculty of Computer Science at Dalhousie University and Adjunct Professor, Anesthesiology and Intensive Care Medicine, at the Charité University Hospital, Humboldt-University, Berlin, Germany. He is Staff Anesthesiologist and Associate Medical Director of Research in the Department of Anesthesia, Pain Management and Perioperative Medicine, Nova Scotia Health Authority, Halifax. Further certifications include Emergency Medicine and a sub-specialization in neuro-anesthesia. Dr. Lehmann has 25 years of experience in experimental and clinical inflammation research including studies on the mechanisms of pain. He established experimental intravital imaging laboratories in Berlin and Greifswald, Germany. His focus of research is the microcirculation, i.e. capillary blood flow, immune cell interactions, and endothelial pathology. He participated in diverse national and international clinical multicenter trials, e.g. in sepsis. He is the author of more than 150 original publications, 5 books, 13 book chapters and almost 200 published abstracts. He joined Dalhousie University in 2007 and currently supervises research in 3 laboratories with modern equipment to study the microcirculation under various conditions experimentally and clinically. He is a member of the Dalhousie Inflammation Group (DIG), the Microcirculation Diagnostics and Applied Studies (MiDAS) research group and the Cystic Fibrosis Translational Research (CFTR) group. In 2009 he founded the RESIST (Research in the Endocannabinoid System in Inflammation, Sepsis and Trauma) group with Dr. Melanie Kelly (Pharmacology) and others at Dal. He and his collaborators received funding for their research on the therapeutic modulation of the endogenous cannabinoid system and for related research projects from CIHR, NSERC, CFI, MITACS, NSHRF, and Innovacorp. Dr. Lehmann is co-founder of Panag Pharma Inc. – a Halifax-based company working on novel cannabinoid formulations for the treatment of pain and inflammation.